

## Monthly DRUP Study Newsletter #80, 01 December 2022

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

---

**It is almost time for a little break...**



**The DRUP team wishes you all a Merry Christmas & a Happy New Year!**

---

## **Study update**

We are almost at the end of 2022 in which we have achieved a lot together. The total number of submitted cases has almost reached 2500 and to more than 50% of these we have been able to offer a treatment within DRUP. The total inclusion has reached 1300 patients so far. The DRUP team looks back on a very successful year!

## **Update study team**

This month we have a few changes to our study team that we would like to inform you about. First of all, our new team member would like to introduce himself;

*Hi everyone! My name is Georgy Gomon and I am the newest addition to the DRUP team. I will be working as a study coordinator from the LUMC and the NKI-AvL. I am 29 years old and I graduated as a medical doctor last month from Leiden University with an interest in Internal medicine. I furthermore have a background in Statistics, having obtained a bachelor in Math and a master in Statistical Science.*



*Since personalized medicine and specifically the DRUP study are very data driven, I hope the DRUP study will offer me the opportunity to combine both of my backgrounds and contribute to the DRUP team.*

Secondly, our colleague Gijs de Wit has unfortunately decided to leave DRUP and go back into the clinic as a resident not in training at the department of internal medicine at the Tergooi hospital. We would like to thank Gijs for his great contribution to the DRUP study and wish him all the best with his new position. Last but not least, our colleague Ilse Spiekman is also leaving us shortly, but only for a little while. She will be starting her pregnancy leave this month. We wish her the best of luck the coming period and are looking forward to have her back again soon!

## **European project**

The European Personalized Cancer project PCM4EU has been awarded and will kick-off on the 1<sup>st</sup> of January 2023. This is an initiative applied for by Hans Gelderblom on behalf of the DRUP team. The coming two years 3 million euros will be made available to implement molecular diagnostics, DRUP-like trials and education in 17 European countries. This new platform allows us to collaborate close with other European DRUP-like trials to fill up cohorts together and in this way be able to conclude whether or not a molecular treatment for a certain tumor type is successful and should be implemented into standard care. A follow-up application has already been submitted for an addition of four more years.

The next issue of the newsletter will include an annual overview of DRUP and can be expected in the first week of 2023! Until then we would like to thank everyone for the great efforts and wish you all a Merry Christmas and a Happy New Year!

Warm regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest

Study Coordinators: Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon

Clinical Project Manager: Lena Bilet

**Table 1: List of pharmaceutical companies & study drugs**

Confidential, list might be subjected to change

**Currently available**

<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>Bayer</u> Regorafenib	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Clovis Oncology</u> Rucaparib	Vemurafenib+ Cobimetinib Vismodegib
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Ribociclib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Palbociclib Talazoparib, dacomitinib Lorlatinib	<u>MSD</u> Pembrolizumab	Atezolizumab+ bevacizumab Alectinib Entrectinib
		<u>Lilly</u> Abemaciclib	
			<u>Janssen</u> Erdafitinib

**Committed**

<u>Lilly</u> Selpercatinib	<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib
-------------------------------	-------------------------	---------------------------

**Calendar & publicity**

December 20<sup>th</sup> Pharma meeting

**Table 2: Submission and accrual overview stage 1,2 & 3 cohorts**

Dec 1<sup>st</sup>, 2022

